Characterization of Degradation Products in Biologics
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Biologic products, unlike small-molecule drugs, have large and complex structures. This makes them susceptible to instability under conditions such as:
Click to read the full article.
Biologics can be formulated in two primary ways:
Click to read the full article.
Biologic formulations, especially those in liquid or reconstituted form, require sterile barriers to maintain their potency and safety. A breach in the container closure system can result in:
Click to read the full article.
Biologic products are particularly sensitive to manufacturing and environmental variations. Even minor changes in formulation, scale, or equipment can affect stability. Stability testing during tech transfer ensures:
Click to read the full article.
HCPs are proteins derived from the host expression system—most commonly Chinese Hamster Ovary (CHO) cells, E. coli, or yeast. These proteins are co-purified with the therapeutic protein and can vary in type and quantity across batches. Their presence poses risks including:
Click to read the full article.
Aggregation refers to the formation of dimers, oligomers, or larger aggregates of protein molecules due to structural instability. It can occur through various pathways and under different stress conditions, including thermal stress, mechanical agitation, freeze-thaw cycles, and changes in pH or ionic strength. Aggregates can be reversible or irreversible and are categorized based on their size:
Click to read the full article.
Unlike small-molecule drugs, biologics such as monoclonal antibodies, enzymes, and vaccines are sensitive to:
Click to read the full article.
